3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the Janus kinase (JAK) inhibitors 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile or 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile, as well as its compositions and methods of use, which is useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, skin disorders, cancer, and other diseases.
50 Citations
64 Claims
-
1-18. -18. (canceled)
-
19. A method of treating a skin disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound selected from 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile;
- and 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile;
according to claim or a pharmaceutically acceptable salt thereof. - View Dependent Claims (21, 22, 25, 26, 58, 59, 60, 61, 62, 63, 64)
- and 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile;
-
20. (canceled)
-
23-24. -24. (canceled)
-
27-57. -57. (canceled)
Specification